FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Inclusion Criteria

• Key Inclusion Criteria: Diagnosis of B-cell lymphoma or CLL as described below: B-Cell Lymphoma: - Histologically documented lymphomas expected to express CD19 and CD20 - Relapsed/refractory disease following prior systemic immunochemotherapy regimen Chronic Lymphocytic Leukemia (CLL): - Diagnosis of CLL per iwCLL guidelines - Relapsed/refractory disease following at least two prior systemic treatment regimens ALL SUBJECTS: - Capable of giving signed informed consent - Age ≥ 18 years old - Stated willingness to comply with study procedures and duration - Contraceptive use for women and men as defined in the protocol Key Exclusion Criteria: ALL SUBJECTS: - Females who are pregnant or breastfeeding - Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2 - Body weight <50 kg - Evidence of insufficient organ function - Receipt therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1 - Currently receiving or likely to require systemic immunosuppressive therapy - Prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T within 6 months of Day 1, or ongoing requirement for systemic GvHD therapy - Receipt of an allograft organ transplant - Known active central nervous system (CNS) involvement by malignancy - Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease - Clinically significant cardiovascular disease - Known HIV infection - Known active Hepatitis B (HBV) or Hepatitis C (HCV) infection - Live vaccine <6 weeks prior to start of lympho-conditioning - Known allergy to albumin (human) or DMSO